|1.||Araie, Makoto: 6 articles (03/2011 - 01/2006)|
|2.||Kitazawa, Yoshiaki: 5 articles (07/2010 - 01/2006)|
|3.||Shirato, Shiroaki: 3 articles (07/2010 - 01/2006)|
|4.||Masuda, Kanjiro: 3 articles (09/2008 - 01/2006)|
|5.||Azuma, Ikuo: 3 articles (09/2008 - 01/2006)|
|6.||Nipradilol-Timolol Study Group: 2 articles (07/2010 - 07/2008)|
|7.||Yamazaki, Yoshio: 2 articles (07/2010 - 07/2008)|
|8.||Ohashi, Yasuo: 2 articles (07/2010 - 07/2008)|
|9.||Watanabe, M: 2 articles (08/2007 - 06/2006)|
|10.||Tokita, Y: 2 articles (08/2007 - 06/2006)|
|1.||Dilated Cardiomyopathy (Cardiomyopathy, Congestive)
05/01/1996 - "This study investigated the therapeutic efficacy of a new beta-blocker, nipradilol, a non-selective agent with vasodilating activity, for the treatment of idiopathic dilated cardiomyopathy (DCM). "
05/01/1996 - "Effect of a new beta-blocker, nipradilol, on cardiac function and neurohumoral factors in idiopathic dilated cardiomyopathy."
01/01/1995 - "This study investigated the therapeutic efficacy of two different beta-blockers, metoprolol (beta 1-selective) and nipradilol (nonselective) for the treatment of idiopathic dilated cardiomyopathy (DCM). "
04/01/1994 - "MIBG-myocardial SPECT was performed on patients with dilated cardiomyopathy (DCM) undergoing treatment with beta blocker (Nipradilol). "
|2.||Hypertension (High Blood Pressure)
07/01/1995 - "Efficacy of long-term treatment with nipradilol, a nitroester-containing beta-blocker, in patients with mild-to-moderate essential hypertension."
10/01/2000 - "These results suggest that exogenous NO from nipradilol reduces the endothelial dysfunction caused by hypertension without changing the blood pressure."
07/01/1995 - "These results suggest that nipradilol is a safe and useful long-term antihypertensive drug in both young and older patients with mild-to-moderate essential hypertension. "
07/01/1995 - "The effects of long-term treatment with nipradilol, a nitroester-containing beta-blocker, on casual and 24-hour blood pressures were studied in 70 patients with mild-to-moderate essential hypertension. "
03/01/1986 - "It is proposed that nipradilol may be beneficial for the treatment of hypertension and coronary heart disease."
|3.||Low Tension Glaucoma
11/01/2008 - "[Long-term study of nipradilol ophthalmic solution in patients with normal-tension glaucoma]."
01/01/2011 - "Retrobulbar hemodynamic effects of nipradilol in normal and normal-tension glaucoma eyes."
11/01/2008 - "Long-term therapy with a nipradilol ophthalmic solution may be useful for treating normal-tension glaucoma."
11/01/2008 - "Among normal tension glaucoma patients who consulted the Nara Medical University Hospital or 2 affiliated hospitals between November 2001 and August 2002, we prospectively examined intraocular pressure-decreasing effects, the deterioration of visual field defects, and the appearance of side effects in 46 patients who underwent single therapy with a nipradilol ophthalmic solution. "
11/01/2008 - "We investigated the long-term clinical effects of a nipradilol ophthalmic solution on normal-tension glaucoma. "
06/01/1997 - "These results suggest that chronic treatment of nipradilol attenuated left ventricular cavity dilation after myocardial infarction and improved cardiac performance."
03/01/2002 - "Nipradilol can prevent left ventricular systolic and diastolic dysfunction after myocardial infarction in rats."
06/01/1997 - "We determined whether chronic treatment with nipradilol, a beta-blocker with vasodilating action, reduces left ventricular cavity dilation (LV remodeling) following myocardial infarction and improves cardiac performance. "
10/01/1992 - "The effect of nipradilol on hemodynamics at rest and during exercise with a multi-stage bicycle ergometer in supine position was studied in 8 male patients suffering from angina pectoris with old myocardial infarction. "
10/01/1992 - "Effect of nipradilol on cardiovascular hemodynamics during exercise in angina pectoris with old myocardial infarction."
11/01/1999 - "These results coupled with evidence that nipradilol does not penetrate the blood-brain barrier indicate that nipradilol exerts an anti-tremor action by blocking peripheral beta2-adrenoceptors."
11/01/1996 - "Improvement of tremor appeared within 2 or 4 weeks after the start of nipradilol therapy, and the efficacy rate, defined as "moderately effective" or over, was 42.5% in all 40 patients, while that defined as "slightly effective" or over was 87.5%. "
11/01/1996 - "Treatment of essential and parkinsonian tremor with nipradilol."
10/01/1996 - "Although 1.0 mg/kg nipradilol significantly reduced the tremor, further inhibition of the tremor was not obtained with dosages up to 2.5 mg/kg of the drug. "
10/01/1996 - "In conclusion, nipradilol was effective for suppressing oxotremorine-induced tremor, as were other beta-blockers."
|4.||DNA (Deoxyribonucleic Acid)
|6.||Nitric Oxide (Nitrogen Monoxide)
|7.||Adrenergic Antagonists (Antiadrenergic Agents)
|10.||Messenger RNA (mRNA)
|2.||Surgical Instruments (Clip)